TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients both sexes,~* Age between 30 and 60 years,~* Metabolic Syndrome according to the IDF criteria~* Waist circumference~* Man ≥90 cm~* Woman ≥80 cm~And two of the following criteria:~* High density lipoprotein~* Man ≤40 mg/dL~* Woman ≤50 mg/dL~* Fasting glucose ≥100 mg/dL~* Triglycerides ≥150 mg/dL~* Blood pressure ≥130/85 mmHg~* Informed consent signed~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to resveratrol~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Previous treatment for the metabolic syndrome components~* Body Mass Index ≥39.9 kg/m2~* Fasting glucose ≥126 mg/dL~* Triglycerides ≥500 mg/dL~* Total cholesterol ≥240 mg/dL~* Low density lipoprotein (c-LDL) ≥190 mg/dL~* Blood Pressure ≥140/90 mmHg

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Banaba (Type: EXPERIMENTAL): Banaba capsules, 500mg, two times per day before meals during 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Calcined magnesia capsules, 500mg, two times per day before meals during 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patient \>18 years old~* Postmenopausal status, documented by prior bilateral salpingo-oophorectomy, or absence of menses \>12 months~* Recurrent urinary tract infections as defined by 3 culture positive urine cultures in the last 12 months, or 2 positive urine cultures in the last 6 months.(Positive urine cultures defined by \>100K colony forming units of 1 or 2 bacterial species on clean catch sample, or \>1000 colony forming units of 1 or 2 bacterial species on sample via straight catheterization).~* Patients on vaginal estrogen must undergo a 1 month washout period prior to initiation of the trial.~Exclusion Criteria:~* Hematuria without appropriate workup~* Pelvic organ prolapse at or beyond the hymen~* Clinically relevant urinary retention~* Pelvic reconstructive surgery within 6 months~* Prior synthetic mesh procedure for pelvic organ prolapse or urinary incontinence~* Clinically relevant nephrolithiasis~* History of breast cancer~* Contraindication to topical estrogen therapy~* Anticoagulation therapy~* Prior pelvic or vaginal radiation therapy~* Prior gynecologic malignancy~* Undiagnosed genital bleeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaginal Estrogen Therapy Group (Type: ACTIVE_COMPARATOR): Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
- Laser Therapy Group (Type: EXPERIMENTAL): Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects (18 to 70 years of age, inclusive) must have a diagnosis of HS for at least~  1 year prior to Baseline~* Stable HS for at least 2 months prior to Screening and also at the Baseline Visit~* Inadequate response to at least a 3-month study of an oral antibiotic for treatment of HS~* Total abscess and inflammatory nodule count \>=3 at the Baseline Visit~* Subject must agree to daily use (and throughout the entirety of the study) of 1 pre-specified over-the-counter topical antiseptics on their HS lesions~* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose~* Male subjects must be willing to use a method of contraception when sexually active, up till 20 weeks after the last administration of study medication~Exclusion Criteria:~* Prior treatment with anti-IL17s or participation in an anti-IL17 study~* Previously received anti-TNFs~* Subject requires, or is expected to require, opioid analgesics for any reason (excluding tramadol)~* Subject received prescription topical therapies for the treatment of HS within 14 days prior to the Baseline Visit~* Subject received systemic non-biologic therapies for HS with potential therapeutic impact for HS less than 28 days prior to Baseline Visit~* Draining fistula count \>20 at the Baseline Visit~* Diagnosis of inflammatory conditions other than HS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bimekizumab (Type: EXPERIMENTAL): Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
- Adalimumab (Type: ACTIVE_COMPARATOR): Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive several placebo applications to keep the blinding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* dupuytrens disease~* xiapex treatment~Exclusion Criteria:~- demens/other psychiatric diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Home-based Program in Improving Sitting Balance and Upper Limb Functions in Patients With Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis with first stroke for more than 6 months~2. Discharge from all rehabilitation services~3. Ability to understand and follow commands~4. A carer able for helping the home program~5. No contraindication to assessment protocol and training~Exclusion Criteria:~1. Cognitive disorder with Abbreviated Mental Test less than 7~2. Unilateral neglect with Star cancellation Test less than 47~3. Sensory deficit~4. Unable to give informed consent~5. Unable to speak either Cantonese or English or Mandarin~6. Commodity that preclude them from undergoing training and assessment~7. Neurological disease other than stroke

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- electrical stimulation with exercises (Type: EXPERIMENTAL): The TENS + TRTT group received TENS simultaneously with the TRTT at home under the instruction of a physical therapist.
- placebo stimulation with exercises (Type: PLACEBO_COMPARATOR): The TENS + TRTT group received placebo-simultaneously with the TRTT at home under the instruction of a physical therapist.
- Control (Type: NO_INTERVENTION): Subjects in this group did not receive any active training. Home safety advice and health education including diet control and blood pressure monitoring were given to the subjects during the home-visit and telephone follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 1 year history of migraine (with or without aura)~* Females of child bearing potential must use acceptable contraception throughout trial~* In general good health based on screening assessment~Exclusion Criteria:~* Pregnant/breast-feeding (or is a female expecting to conceive during study period)~* History or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency virus (HIV) disease~* Major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)~* History of gastric, or small intestinal surgery, or has a disease that causes malabsorption~* History of cancer within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telcagepant 280 mg/300 mg (Type: EXPERIMENTAL): Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
- Rizatriptan 10 mg (Type: ACTIVE_COMPARATOR): Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Newly-diagnosed with absence epilepsy and never been treated with Anti-epileptic drugs (AEDs).~* Diagnosis demonstrated on one of two 5-minute hyperventilation tests.~* Investigator must judge that the subject and parent/guardian are likely to comply with all study procedures.~* Parent/guardian must given written informed consent. Subjects who are intellectually able to understand the concepts and procedures of the protocol must give assent by also signing the consent or by signing a separate assent form.~* Results of all screen assessments are judged to be clinically acceptable to the investigator and do not indicate any reasons why entry into the study would be contraindicated.~Exclusion criteria:~* Seizures are the result of a currently active, known, and identifiable intracerebral lesion.~* Has partial or generalized tonic-clonic seizures.~* Has a progressive neurological disorder defined as being unstable for at least 12 weeks prior to the Screen Phase.~* Has a psychiatric disorder requiring medication, or has had a past psychiatric condition that was both judged to be severe and required hospitalization.~* Has any clinically significant chronic cardiac, renal, or hepatic medical condition.~* Has a condition that affects the absorption, distribution, metabolism, or excretion of drugs.~* Is currently taking any psychoactive drugs to treat hyperactivity disorder or attention deficit disorder.~* Has taken any investigational drug within 12 weeks prior to the Screen Phase.~* Is sexually active.~* Is either pregnant (i.e., confirmed by pregnancy test at Screen) or breastfeeding.~* Has a clinically significant chronic medical disorder which the investigator and/or GSK medical monitor determine warrants exclusion.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Subjects receiving lamotrigine (Type: EXPERIMENTAL): Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient men and women age 18 and older~* Diagnosis of BDD within 6 months of study start date based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)~* Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale~* Lives within driving distance of Boston, MA or Providence, RI~Exclusion Criteria:~* Suicidal or homicidal tendencies~* Alcohol/drug abuse or dependence within 3 months of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
- Placebo (Type: PLACEBO_COMPARATOR): Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged 18 to 80 years inclusive at the time of informed consent~2. Subjects must have non-malignant chronic pain treated with opioids and must have opioid-induced constipation (OIC)~3. Subjects must be treated with a stable opioid regimen at a total daily dose on average of ≥ 30 mg equivalents of oral morphine sulfate~4. Subjects must not be currently using laxatives or must be willing to discontinue laxative use at Screening and must be willing to use only the rescue laxatives provided throughout the study duration~5. Subjects must meet opioid-induced constipation criteria based on the Bowel Movement and Constipation Assessment (BMCA) Diary~Exclusion Criteria:~1. Evidence of significant structural abnormalities of the gastrointestinal (GI) tract~2. Evidence of active medical diseases affecting bowel transit~3. History or presence of pelvic disorders that may be a cause of constipation~4. Surgery (except for minor procedures) within 60 days of Screening~5. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g., mechanical GI obstruction)~6. Subjects who have never taken laxatives for the treatment of OIC~7. History of active treatment for cancer within the last 2 years (except for basal cell or squamous cell carcinoma of the skin that have been successfully resected) or tamoxifen \[Nolvadex®\] and raloxifene \[Evista®\] when being used for prevention of breast cancer~8. Current use of any prohibited medication including opioid antagonists, partial agonists or mixed agonists/antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naldemedine (Type: EXPERIMENTAL): Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed locally advanced or metastatic (stage=IIIB/IV) non-small cell lung cancer (NSCLC) before the front line chemotherapy. Note: sputum cytology alone is not acceptable~* Patients have completed 4 cycles of first line platinum contained doublet chemotherapy without progression or intolerable toxicity.~* Patients with PR or SD on study entry need to have one or more measurable lesions according to RECIST criteria.~* The study treatment should be started at least 3 weeks (21 days) but no more than 6 weeks (42 days) since last dose of chemotherapy, and within 4 weeks (28 days) since last tumour assessment.~Exclusion Criteria:~* Prior exposure to monoclonal antibodies or small molecule inhibitors against EGFR receptors. (e.g. gefitinib, erlotinib, C225)~* Patients with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they are clinically stable and have been discontinued from steroid therapy for at least 4 weeks prior to first dose of study medication.~* Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)~* Known biomarker status of one or more of the following: Tumour EGFR gene copy number, tumour EGFR gene mutation status, tumour EGFR protein expression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gefitinib (Type: EXPERIMENTAL): Gefitinib (Iressa® 250 mg) 1 tablet daily
- placebo (Type: PLACEBO_COMPARATOR): placebo 1 tablet daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age at day of consent;~* Is a male, or is a non-pregnant non-lactating female who is either of non-child-bearing potential, or is using adequate means of birth control;~* Has a h/o of urinary incontinence from neurogenic bladder of spinal cord injury etiology;~* Has impairment based on the American Spinal Injury Association (ASIA);~* Use clean intermittent catheterization;~* Has urinary incontinence between scheduled catheterization;~* Capable of understanding and complying with the protocol.~Exclusion Criteria:~* Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency;~* Have any medical condition that precludes their participation in the study, or may confound the outcome of the study;~* History of major lower urinary tract surgery, procedures;~* Has an active skin disorder, affecting TDS application site areas;~* Hypersensitivity to the investigational drug;~* Has participated in any study involving administration of an investigational compound within 30 days before this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxybutynin transdermal system (Type: EXPERIMENTAL): Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete